Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study

摘要

Background: Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this studyudwas to survey the natural history of bone metastasis in CRC.udPatients and methods: This retrospective, multicenter, observational study of 264 patients with CRC involving boneudexamined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency,udzoledronic acid therapy, and disease outcomes.udResults: Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the mostudcommon site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time fromudCRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiationudand pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs.udPatients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival.udSubgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versusud1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid.udConclusion: This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid inudthis setting.